Boehringer Ingelheim Announces Several Idiopathic Pulmonary Fibrosis Presentations at Upcoming International Scientific Meeting

Boehringer Ingelheim Announces Several Idiopathic Pulmonary Fibrosis Presentations at Upcoming International Scientific Meeting

Boehringer Ingelheim Pharmaceuticals, Inc. recently announced in a press release that the company will present 29 abstracts on respiratory disorders at the 2015 American Thoracic Society (ATS) International Conference in Denver, May 15-20. The company will present the latest data on their investigational drug portfolio for disorders like chronic…

Two Gene Mutations Linked with Telomeres in Pulmonary Fibrosis

Hard at work in the laboratory of Dr. Christine Kim Garcia, Associate Professor of Internal Medicine at UT Southwestern Medical Center, is a group of researchers studying familial pulmonary fibrosis. The disease is characterized by fatal lung scarring and is now associated with mutations in two genes: PARN and RTEL1.

Pulmonary Fibrosis Foundation Announces Registration For International Conference On PF

The Pulmonary Fibrosis Foundation (PFF) recently announced that registration for PFF Summit 2015: From Bench to Bedside is now open. This is an international conference focused on pulmonary fibrosis (PF), a deadly disease that results from lung scarring. The Summit will address medical education for healthcare professionals, conduct sessions dedicated to those that live with…

New iBio, Caliber Collaboration Accelerating Development of Clinical Studies For Anti-Fibrosis Therapy

iBio, Inc, a leading pharmaceutical company using plant-based technology for developing and manufacturing biological products, has announced that it is now collaborating with Caliber Biotherapeutics LLC, which will be responsible for scaling-up and producing the necessary equipment for clinical development of iBio, Inc.’s lead anti-fibrosis product, IBIO-CFB03.

Veracyte Closes $40 Million Private Placement Transaction

Molecular diagnostics company Veracyte, Inc., which is developing a genomic test to help improve diagnosis of Idiopathic Pulmonary Fibrosis (IPF) has announced the establishment of a definitive agreement for the trade of common stocks, worth $40 million, in a private placement. Investors acquired 4,907,975 shares of common stock at a purchase price of…

New Veracyte/GE Partnership May Lead To Improved IPF Diagnosis

The molecular diagnostic company Veracyte, Inc. and the multinational conglomerate corporation GE have established a research partnership focused on developing novel solutions able to improve the diagnosis of diseases such as Idiopathic pulmonary fibrosis (IPF). The companies did not disclose the financial terms of the collaboration. Veracyte will work…

Pacific Therapeutics gets US Patent Office Notice Of Allowability for Pulmonary Fibrosis treatment

Pacific Therapeutics Ltd., a clinical stage pharmaceutical company that leads programs focused on erectile dysfunction and diseases of excessive scarring (fibrosis), announced that the US Patent Office (PO) has released a Notice Of Allowability for the Company’s patent application, Compositions and Methods for the treatment of fibroproliferative conditions. Doug Unwin,…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums